Helgi van de Velde

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease”.

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

UNC Libraries(2020)10.17615/tfn8-cp59

N/A

0DataRank · unranked

0 citations

Ming Qi, Peter M. Voorhees, Frits van Rhee, Razelle Kurzrock, Luis Fayad +5 more

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

UNC Libraries(2020)10.17615/tmgg-w910

N/A

0DataRank · unranked

0 citations

Suzanne Lentzsch, Pieter Sonneveld, Sonja Zweegman, Hong Xie, Xiang Qin +13 more

Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Cancer Research Communications(2024)10.1158/2767-9764.crc-23-0434

N/A

0DataRank · unranked

18 citations

Lauren T. Reiman, Olivia Perez de, Sarah E. Parzych, Peter A. Forsberg, Peter Kim +5 more